Welcome
Support Centre
02 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Comparison between immune response to different modes of vaccination: intradermal and subcutaneous yellow fever vaccination
ISRCTN ISRCTN46326316
ClinicalTrials.gov identifier
Public title Comparison between immune response to different modes of vaccination: intradermal and subcutaneous yellow fever vaccination
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis Intradermal yellow fever vaccination with a reduced dose will induce a sufficient protective immunological response comparable to the response elicited by subcutaneous yellow fever vaccination.
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment The Netherlands
Disease/condition/study domain Yellow Fever
Participants - inclusion criteria Healthy volunteers, greater than 18 years (previously and not previously vaccinated with yellow fever vaccine)
Participants - exclusion criteria 1. Pregnancy
2. Diabetes mellitus
3. Use of immunomodulating medication, e.g. corticosteroids
4. Cytostatica
5. Use of chloroquine
Anticipated start date 15/06/2005
Anticipated end date 15/06/2006
Status of trial Completed
Patient information material
Target number of participants 120
Interventions Subcutaneous of intradermal yellow fever vaccination.
Primary outcome measure(s) 1. Protective humoral immune response
2. For first time vaccinees measured 4 and 8 weeks post-vaccination, for revaccinees measured 2 weeks post-vaccination.
3. All sera will be analysed by ELISA, Immunofluorescence and plaque reduction assay.
Secondary outcome measure(s) Adverse events measured for three weeks post-vaccination by keeping a diary, viremia measured 5 days post-vaccination by RT-PCR.
Sources of funding 1. Leiden University Medical Centre (LUMC) (The Netherlands) - Department of Infectious Diseases
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/pubmed/18431480
Contact name Dr  A.H.E.  Roukens
  Address Leiden University Medical Centre (LUMC)
Albinusdreef 2, C5-P
  City/town Leiden
  Zip/Postcode 2333 ZA
  Country Netherlands
  Email a.h.e.roukens@lumc.nl
Sponsor Leiden University Medical Centre (LUMC) (Netherlands)
  Address Albinusdreef 2
P.O. Box 9600
  City/town Leiden
  Zip/Postcode 2300 RC
  Country Netherlands
  Email
  Sponsor website: http://www.lumc.nl/
Date applied 20/12/2005
Last edited 25/04/2008
Date ISRCTN assigned 20/12/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central